CortexBio Insights — Rare Disease & Metabolic Health Research

CortexBio In Consult

The Ageing Fatigue Pipeline Stalled. Here Is Why.

In Practice gave clinicians the five signatures. This tier gives decision-makers the strategy: why fatigue trials keep failing, how enrichment fixes it, and where rare disease unlocks the biology.

CortexBio In Practice

Reading the Five Fatigue Signatures in Clinic

In Brief made the case that ageing fatigue is five biologies, not one. Here is how to recognise each signature in clinic — and align it to a biomarker and an outcome measure.

CortexBio In Brief

Tiredness Is Not One Thing. It Is Five.

Older adults are told they are simply tired. But ageing fatigue is at least five different biologies wearing one clinical label — and that matters for what works.

Diagram illustrating pavement camber angle and its effect on knee joint loading

CortexBio In Brief

263,865 joint replacements. An NHS waiting list over 800,000.

Britain's crumbling pavements tilt beyond legal limits — loading knees asymmetrically with every step. The infrastructure variable medicine has overlooked.

CortexBio In Practice

How asymmetric loading from cambered pavements drives molecular ageing

In Brief made the case that pavement crossfall loads joints asymmetrically. Here is the clinical evidence: the biological cascade, across 18 peer-reviewed studies, and the NHS waiting-time data.

CortexBio In Consult

Cambered pavements as a chronic metabolic stressor

In Practice assembled the clinical evidence. This tier maps the complete molecular cascade from asymmetric joint loading to systemic ageing markers, with intervention timing and the clinical framework.

Original research and analysis on rare disease, metabolic health, and the biology of ageing. By Dima Martini-Drew MD, physician-scientist and founder of CortexBio.

Latest